Comparative Pharmacology
Head-to-head clinical analysis: BYSTOLIC versus ZEBETA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYSTOLIC versus ZEBETA.
BYSTOLIC vs ZEBETA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bystolic (nebivolol) is a beta-1 selective adrenergic receptor antagonist with additional nitric oxide-mediated vasodilatory effects. It decreases heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart and kidney, and enhances nitric oxide release from vascular endothelium via beta-3 receptor activation.
Selective beta-1 adrenergic receptor antagonist (cardioselective beta-blocker). Reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
Oral: 5 mg once daily; may increase at 2-week intervals to 10 mg, 20 mg, 40 mg; maximum 40 mg/day.
Initial dose 5 mg orally twice daily; may increase to 10 mg twice daily after 2 weeks; maximum 20 mg twice daily.
None Documented
None Documented
Terminal elimination half-life: 10-12 hours; allows once-daily dosing in most patients; steady-state achieved in 3-5 days
Terminal elimination half-life is 12–15 hours in patients with normal renal function, allowing once-daily dosing.
Renal: 38% unchanged; hepatic metabolism: extensive; fecal: minor; total renal clearance accounts for 30-50% of dose
Approximately 50% of an oral dose is excreted unchanged in urine; the remainder is hepatically metabolized with biliary excretion of metabolites contributing to fecal elimination.
Category C
Category C
Beta Blocker
Beta Blocker